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ABSTRACT
Congestive Heart Failure (HF) is a chronic progressive cardiac disorder with high mortality rates
and is the number one reason for hospital readmission in the United States. More than 5 million
Americans live with HF with more than 900,000 new diagnoses annually. The likelihood of
developing HF increases with age making it the most common primary diagnosis for patients
over age 65. HF has a significant impact on quality of life, with depression being a common
comorbid condition. Thoracic impedance monitoring has shown to reduce exacerbations and
hospitalizations in patients with HF. This project evaluated the literature related to impedance
monitoring in the management of HF. The projected outcome for this project is to demonstrate
the state of evidence regarding the effect of impedance monitoring on 30 day hospital
readmission rates.
Keywords: impedance monitoring, heart failure, readmissions, costs, transitions theory, and
quality of life
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Evaluating Impedance Monitoring to Reduce Hospital Readmissions for Patients with
Heart Failure with Reduced Ejection Fraction: An Integrative Review
Heart Failure (HF) is a chronic progressive cardiac disorder with high mortality rates and is
the most frequent reason for hospital readmission in the United States (U.S.) (Ivany & White,
2013). More than 5 million Americans live with HF with more than 900,000 new diagnoses
annually (CDC, 2016). The likelihood of developing HF increases with age making it the most
common primary diagnosis for patients over age 65 (CDC, 2016). About half of all HF diagnoses
are heart failure with reduced ejection fraction (HFrEF) (Savarese & Lund, 2017). Thoracic
impedance monitoring is a tool that is used to identify and predict heart failure exacerbations and
prevents hospital readmissions (Franchuk, 2017). On average, the fluid index of impedance
monitoring starts to rise 14 days prior to symptom onset (Yu, et al., 2005). Impedance
monitoring in patients with HFrEF is not considered the standard of care despite there being
evidence to support its use. The current recommendation for impedance monitoring frequency is
every 3-12 months (Wilkoff, et al., 2008). This scholarly project sought to evaluate the state of
evidence regarding more frequent impedance monitoring in patients with HFrEF at high-risk for
hospital readmission who have an existing implanted cardiac device with impedance monitoring
capability.
Background
HF is a chronic progressive cardiac disorder that is characterized by the reduced ability of the
heart to pump and/or fill with blood, which results in inadequate cardiac output to meet the
metabolic demands of the body (Savarese & Lund, 2017). HF has been recognized as a global
pandemic and affects nearly 26 million people worldwide and nearly 6 million people in the U.S.
(Savarese & Lund, 2017). The likelihood of developing HF increases with age making it the
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most common primary diagnosis for patients over age 65 (CDC, 2016). Every year in the U.S.
there are over 900,000 new cases of HF. Heart disease is the leading cause of HF (Savarese &
Lund, 2017). The prevalence of developing HF is projected to rise because of the ageing
population which will likely result in increased hospitalization rates and health care costs
(Savarese & Lund, 2017). Alternative treatment and therapies are needed (Savarese & Lund,
2017). HF is classified into three subtypes according to left ventricular function: HFrEF, HF with
preserved ejection fraction (HFpEF), and HF mid-range ejection fraction (HFmEF). The
diagnostic criteria for HFrEF is left ventricular ejection fraction (LVEF) <35%. The diagnostic
criteria for HFpEF is LVEF 55-65%. The diagnostic criterion for HFmEF is LVEF 40-55%
(Nadruz, 2016). This scholarly project will be focusing on patients with HFrEF.
Due to the chronic nature of HF, it is difficult to medically and self-manage. Additionally,
there are a variety of etiologies that can result in HF with risk factors including heart disease,
smoking, and hypertension (CDC, 2017). Diagnostics that are currently used to assist in
identifying and monitoring HF include biomarkers such as the b-type natriuretic peptide,
echocardiography, 12-lead electrocardiography, echocardiography, and radiography (Coller,
Campbell, Krum, & Prior, 2013). A combination of therapies and disciplines is needed to
provide optimal care. Patient participation and understanding is critical to positive outcomes
(Riley & Masters, 2016). Lifestyle changes that often need to be made include a low sodium diet,
fluid restrictions, and daily weight monitoring (AHA, 2017). Patients are often prescribed up to
five medications, which are considered guideline-directed medical therapy. These medications
include a diuretic, selected beta-blockade, ace-inhibitor, aldosterone antagonist, and sometimes
digoxin (AHA, 2017). Many HF patients have a history of other cardiac illness such as
myocardial infarction, hypertension, and arrhythmia. The diagnosis of HF can be very difficult
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for patients to cope with and depression is a common comorbid condition. Nearly one in five
patients with HF also have a diagnosis of depression (Mbakwem, Aina, & Amadi, 2016). A
diagnosis of HF directly impacts a patient’s quality of life and is a major transition in a patient’s
life. Hospital admissions and readmissions can be indirectly related to quality of life, so
improvement processes around readmission reduction are multifocal to reduce costs and improve
quality of life.
One of the major reasons why there is so much emphasis on reduction of readmissions is
because patients with HF who suffer from a 30 day readmission have a worse prognosis (Tung,
et al., 2016). This underscores the importance of reducing readmissions as a means to improve
HF outcomes (Tung, et al., 2016). Early identification of acute decompensated HF (ADHF)
allows for early intervention and management. Methods for managing patients on an outpatient
basis are continuing to be explored for patients with HF. Intravenous diuretic therapy is used as a
more aggressive outpatient treatment option (Buckley, et al., 2016). Ideally, identification of
ADHF happens early and treatment can be started quickly in the outpatient environment,
preventing a readmission (Buckley, et al., 2016). Impedance monitoring is a way to identify
patients who need early intervention for HF. Other interventions that can be implemented early
for patients with HF include quality of life assessment, patient education on self-care behaviors,
and referral to transitional care programs, such as home health care (Feltner, et al., 2014).
Patients with HF undergo altered quality of life due to serious physical limitations and
decreases in functional capacity (Marques de Sousa, dos Santos Oliveira, Oliveira Soares,
Amorim de Araújo, & dos Santos Oliveira, 2017). Awareness of a patient’s thoracic impedance
can enable clinicians to monitor quality of life in their patient population in addition to treatment
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options. The Minnesota Living with Heart Failure Questionnaire (MLWHF) is the most widely
used quality of life assessment tool for patients with HF (Marques de Sousa, et al., 2017).
Patient education, with self-care being critical to positive outcomes, is also an integral part of
HF management. Low sodium diets (He & MacGregor, 2011), monitoring of daily weights,
medication adherence, fluid intake, and exercise are just a few of the self-care techniques that are
taught to patients with HF (AHA, 2014). Management of symptoms through a low sodium diet is
a finding that has been consistent in a large number of studies and He & MacGregor (2011)
conducted a meta-analysis of outcomes trials to confirm this finding. This study’s purpose was to
highlight that a behavior can reduce cardiovascular risk and it’s primary objective was to review
the importance of reducing salt intake on cardiovascular health. The World Health Organization
(WHO) supports this consensus and salt reduction is one of the top three priorities to tackle the
non-communicable disease crisis (He & MacGregor, 2011). Reduction of salt intake is one of the
primary education points in symptom management for patients with heart failure (CDC, 2016).
Another component to care transitions is the utilization of home health services. HF patients
that are discharged to a home health care service and who have early physician follow-up have
been shown to have a reduced readmission rate (Murtaugh, et al., 2017). Additionally, patients
with HF who received interventions based on their thoracic impedance monitoring combined
with home health care had fewer 30 day readmissions than patients who only received home care
(Shapiro, et al., 2017).
Because HF is increasing in prevalence and is associated with high mortality and morbidity
there is significant associated personal and societal burden. Functional decline and increasing
dependence on others mark the transition for a more palliative approach with goals of care
around quality of life and symptom management. Patients and caregivers recognize that heart
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failure is a series of transitions (Jones, Nowels, Sudore, Ahluwalia, &Bekelman, 2015).
Transition theory has been identified as an applicable nursing theory that offers hope during this
time of transition. This theory helps clinicians, patients, and families adjust to the challenges of a
diagnosis of HF and navigate the illness trajectory. Maintaining Hope in Transition is a
theoretical framework stemming from Transitions Theory and is useful in the care of patients
with HF. Key factors described include acknowledging circumstances, restructuring reality,
dealing with vulnerability, achieving normalization, and resolving uncertainty. Incorporating
theory into the plan of care can help assist clinicians and providers with care planning and
focused interventions for patients and families from diagnosis to advanced stages (Davidson,
Dracup, Phillips, Padilla, & Daly, 2007). It is important to consider each care option that is
available to a patient.
Palliative care is another important option to consider in the management of heart failure.
Many clinicians are still learning the palliative care needs of their patients. This integrative
review includes this topic in the discussion because of the focus on transitions of care.
Impedance monitoring can be utilized to help clinicians manage HF and may guide the treatment
plan even towards palliative care in the event that advanced therapies are not options and HF has
negatively impacted the quality of life of the patient and their family (Ivany & White, 2013).
This poor prognostic diagnosis encourages the need to continue to study ways to improve
outcomes for patients with HF. Despite the chronic and progressive nature of HF there are
barriers to providing palliative care. It is challenging dealing with the diagnosis of heart failure,
and many patients are alarmed by the term palliative care (Ivany & White, 2013).
Some patients with HF have been implanted with cardio-defibrillators (ICD) or cardiac
resynchronization therapy with cardio-defibrillator (CRT-D) devices. For nearly 10 years experts
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have been recommending the use of pacemaker technology in the management of cardiac
patients (Toogood, 2007). It is estimated that over 3 million Americans have a pacemaker, and
nearly 600,000 pacemakers are implanted annually (Wood, & Ellenbogen, 2002). Thoracic
impedance is a function of many pacemakers and ICD’s that are used today. ICD’s are indicated
in patients with HFrEF with LVEF less than 35% and cardio-resynchronization therapy with
defibrillator (CRT-D) are indicated for LVEF less than 35%, New York Heart Association
(NYHA) class II-IV, normal sinus rhythm with the QRS greater than or equal to 150ms with a
left bundle branch block pattern (Yancy, et al., 2017). The American College of Cardiology,
American Heart Association, and Heart Rhythm Society Guidelines recommend that a
pacemaker should be followed-up every 3-12 months, and those with ICD’s should be followed
up every 3-6 months, with more frequent follow-ups as the battery approaches elective
replacement (Wilkoff, et. al., 2008). While this is fairly frequent, this follow-up can occur
remotely, termed remote monitoring, which can reduce the number of office visits a patient
would need to make. In addition to battery monitoring, the pacemakers and ICD’s can monitor
arrhythmias, and lung fluid accumulation, or impedance monitoring (Burri & Senouf, 2009).
Thoracic impedance monitoring provides the clinician with fluid thresholds within the chest wall
of patients and can alert the provider to threshold crossings that indicate fluid overload, or acute
decompensated heart failure (ADHF) (Blair, 2014). This review will demonstrate the state of
evidence related to impedance monitoring on 30 day hospital readmission rates.
Impedance monitoring is not currently a guideline recommended therapy, however, there are
extensive randomized controlled trials and cohort studies that support its use (Blair, 2014;
Shochat, et al., 2017; Miyoshi, et al., 2017). Impedance monitoring frequency varies in clinics
across the U.S.; however, more frequent monitoring could provide an opportunity for earlier
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intervention in those who are experiencing fluid overload and prevent 30 day hospital
readmission (Coller, 2013). The national average for 30 day HF hospital readmissions is 21.6%
in the U.S. (CMS, 2017). Many hospitals aim to achieve a readmission rate that is less than or
equal to the national average for reimbursement purposes from Medicare (AHA, 2017).
Problem Statement
HF is a chronic progressive disease that results in physical, emotional, and financial
burdens for individuals and healthcare systems (Ivany & White, 2013). On average, 50% of
patients with HF who have a HF hospital admission will be readmitted within 6-months, and
nearly 21.6% are readmitted within 30 days (CMS, 2017). Increased impedance monitoring is
not a routine surveillance to predict HF exacerbations despite evidence demonstrating reduced
HF exacerbations and hospitalizations (Tung, et al., 2016). This integrative review helps inform
providers regarding the most recent and best evidence available in incorporating thoracic
impedance monitoring for the care of patients with heart failure. An integrative review is
valuable to providers because it reviews what is known about a subject, examines the quality of
the information, determines what additional information should be known, and provides a
recommendation for next steps in research and practice (Holly, Salmond, & Saimbert, 2017).
Purpose & Significance of the Scholarly Project
The purpose of this project is to evaluate the literature related to impedance monitoring in
patients with HF on 30 day hospital readmissions and quality of life. The principle aim is to
provide a synthesis of the evidence and make a recommendation to cardiovascular clinicians.
Goals and Objectives
•

Objective 1: To provide an integrative review of the literature related to the effectiveness
of remote impedance monitoring in reducing 30 day HF hospital readmissions.
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Objective 2: To provide a recommendation for remote impedance monitoring for
outpatient management of HF.
Clinical Questions

This integrative review will address the following clinical questions:
1. In patients with HFrEF who have an impedance monitoring device, does impedance
monitoring reduce hospital 30 day readmission rates?
2. In patients with HFrEF who have an impedance monitoring device, does impedance
monitoring impact quality of life?
Questions to support and maintain the focus of this review:
1. Are there any studies that evaluate the effect of impedance monitoring on quality of life?
2. Does increased impedance monitoring improve quality of life?
3. Is there a nursing theory that can be applied to thoracic impedance monitoring and heart
failure care?
4. Does impedance monitoring identify early heart failure?
5. Does impedance monitoring decrease readmissions?
Methods
Integrative Review Framework: Whittemore & Knalf
The integrative review updated methodology by Whittemore and Knalf (2005) acted as
the framework for this integrative review. This methodology distinguishes the integrative review
from other review methods and allows for the combining of diverse methodologies, including
empirical and theoretical, in the review (Whittemore & Knalf, 2005). Integrative reviews are the
broadest type of research review and allow for the simultaneous inclusion of experimental and
non-experimental research in order to fully encompass the information. This framework includes

IMPEDANCE MONITORING IN HEART FAILURE

19

the problem identification stage, data collection, literature search stage, data evaluation stage,
data analysis stage, conclusion drawing and verification, and presentation stage. In addition to
Whittemore and Knalf (2005), each manuscript was assigned a level of evidence (LOE)
according to Melnyk’s system of hierarchy (Appendix A). In addition to the integrative review
methodology, Transitions Theory acted as the theoretical framework and is discussed in detail in
this section.
Problem identification stage. The problem identification stage is the first step in the
integrative review methodology. This stage is where a clear identification of the problem that the
review is addressing occurs. This step provides focus and boundaries for the integrative review
process (Whittemore & Knalf, 2005). This integrative review stems from the burden of heart
failure on patients and healthcare systems. Its purpose is to analyze the literature related to a tool
that can be used to manage heart failure and reduce the burden on both patients and healthcare
systems. During the problem identification stage, data can be gathered from validated
information sources to help guide the focus of the review. Hospital Compare’s, a national
Medicare database, 30 day readmission rates were used to support this integrative review’s
identified problem of higher readmission rates in patients with HF.
Literature search stage. The next phase of the Whittemore & Knalf (2005) framework
is the literature search stage. When performing an integrative review well defined search
strategies are used to ensure there is a complete and unbiased search. The methodology of the
literature search process is shared in the results section of this paper, including search terms,
databases used, and inclusion and exclusion criteria for determining relevant primary sources.
This integrative review’s search process was systematic in nature and included a discussion of
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clinical guidelines, systematic reviews, clinical trials, cohort studies, literature reviews, and
theory discussion.
Data evaluation stage. The data evaluation stage reviews the types of studies included in
the paper in order to evaluate the overall quality of the search. This includes identification of
clinical guidelines, systematic reviews, clinical trials, cohort studies and whether or not the
primary sources used a mixed method or qualitative research, versus a quantitative research
method (Whittemore & Knalf, 2005). The quality of the studies for this review are organized in
an evidence table using Melnyk’s hierarchy of evidence (Appendix A). The researcher also used
specific selection criteria to help identify and structure the types of articles found.
Data analysis stage. In the data analysis stage the data in research reviews are ordered,
coded, categorized, and summarized into a unified and integrated conclusion about the research
problem. This enables the researcher to organize the evidence in an unbiased manner and provide
innovative synthesis of the evidence. This stage encompasses data reduction, data display, and
data comparison (Whittemore & Knalf, 2005). The articles for this integrative review are
organized and discussed in a hierarchical format based on the level of evidence.
Data reduction. Data reduction is the determination of a classification system for
managing data from diverse methodologies; for example, an integrative review includes
information that is both qualitative and quantitative in nature. Primary sources are divided into
subgroups according to some logical system to facilitate analysis (ex: qualitative/descriptive
studies in one group). Sources can also be based on chronology, settings, and sample
characteristics and are analyzed by topic. This organized technique enables the researcher to
extract and code data into a manageable framework (Whittemore & Knalf, 2005).
Predetermined/relevant data of each subgroup classification are extracted and complied into a
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spreadsheet, which demonstrates succinct and organized literature, facilitating systematic
comparison on issues, variables, and sample characteristics (Whittemore & Knalf, 2005). This
integrative review utilized an evidence table organized into subgroups that classifies the level of
evidence, type of study, and other characteristics.
Data display. Displaying data is a way to show how the data from multiple varying types
of studies shares results. This can be done using graphs, tables, and charts (Whittemore & Knalf,
2005). This integrative review utilized tables and figures to help display the literature from
varying types of studies.
Data comparison. Once data is organized and displayed the researcher can examine the
displays for patterns, themes, or relationships. Concept mapping is another tool that can be used.
Either tool used for data comparison helps to provide clarity for the empirical and/or theoretical
components in the literature allowing support to emerge from early interpretive efforts
(Whittemore & Knalf, 2005). This integrative review utilized an evidence table to organize the
literature based on levels of evidence. The researcher found and displayed themes and
commonalities in a flowchart.
Conclusion drawing and verification. After the data is compared, the researcher can
then draw conclusions by isolating patterns and processes as well as commonalities and
differences in the literature. These conclusions must be verified with the primary source for
accuracy. In the event of conflicting evidence, the need for further research with subsequent
research questions aimed at resolving the conflict is recommended. Important elements and
conclusions are synthesized and integrated into a summation. It is recommended that the entire
process be documented so that thoughts, analytical hunches, and alternate hypotheses are
incorporated as possibly relating to the interpretation of the data (Whittemore & Knalf, 2005).
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This integrative review utilized the evidence table and flowcharts to help draw a conclusion
regarding a recommendation for providers related to impedance monitoring in patients with heart
failure.
Presentation Stage. Lastly, the findings from the review are reported in explicit detail to
provide a logical chain of evidence. Information that is already known is shared as well as the
new information that the integrative review has added to the body of evidence and how it
impacts or changes the existing general consensus (Whittemore & Knalf, 2005). This integrative
review adds to the body of evidence by providing an extensive review of the literature and other
concepts related to impedance monitoring and patients with HF.
Theoretical Framework: Transitions Theory
This review has adopted a theoretical framework for support. A theoretical framework is
helpful for the review because it can be used to define and guide variables and the relationships
between the variables. A theoretical framework can help with evaluation of outcomes and
providing directions for care (Smith & Liehr, 2014). Transitions Theory was used as the
theoretical framework for this review. Transitions Theory offers a guideline and framework for
the various transitions in a patient’s life. Also, this theory has an essential foundation within the
nursing profession. A review of the literature was performed to identify supporting articles
related to heart failure and Transitions Theory. Few articles were found and focused on palliative
care, transitions prior to a cardiac procedure, and discharging from hospitals.
Afaf I. Melieis developed Transitions Theory through research with immigrants and the
transitions they face when they enter the U.S. (Meleis, 2010). The purpose of the theory is to
describe, explain, and predict experiences of people in types of transitions including health and
illness, situational, developmental, and organizational (Smith & Liehr, 2014). Key theory
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concepts describe the types and patterns of transitions an individual may go through. These
transitions span the lifetime, from birth to death. Additionally, this theory identifies properties of
transition experiences, such as an illness from which the individual is suffering. Transition
conditions, patterns of response, and process and outcomes indicators are also concepts described
in the theory. Nursing therapeutics are embedded throughout each transition. There is also a
relationship between the concepts as the individual moves through life. This theory has been a
popular nursing theory because it can be used in nursing practices for people across unique
health-related transitions (Smith & Liehr, 2014).
Transitions Theory applies to patients with HF because they are they dealing with a
serious health condition and learning how to manage this can be a difficult transition. The
diagnosis itself is a transition and patients are sometimes faced with end-of life decisions. After
diagnosis, there are markers of disease progression and transition, for example functional decline
and increased dependence on others. This signals the need to transition their care to meet the
patient’s needs (Davidson et al. 2007). Nurses, at all levels, play a central role in the lives of
patients as they journey through life’s transitions. Nurses can aid in positive transitions by
providing education, support, and/or direct care, thereby reducing disease and health risk.
Additionally nurses enhance health and wellbeing and can assist those individuals as they move
through transitions (Smith & Liehr, 2014). Impedance monitoring is a tool that can be used by
clinicians and patients with HF to help them as they are dealing with their transition of managing
a chronic disease (Blair, 2014). Patients with HF deal with a transition at diagnosis, from hospital
to home, and throughout their disease process, which in many cases leads to subsequent
admissions and end-of life. Transitions Theory will guide this review and careful attention will
be paid to the transition from hospital to home and outpatient management.
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Types and patterns. Transitions Theory has five concepts that will be related to this
review. The first concept discusses the types and patterns of transitions an individual faces.
During a lifetime an individual is faced with many transitions, including developmental, health
and illness, situational, and organizational (Meleis, 2010). A diagnosis of HF is a major
transition for an individual. Most people with this diagnosis are over the age of 65; however,
older age does not make the adjustment easier. There are also individuals who are diagnosed
with HF at a young age and undergo extensive treatment options such as a left-ventricular assist
device and/or heart transplantation. A diagnosis of HF is characterized by a chronic progressive
pattern of exacerbations and remissions evidenced by hospitalizations. This complex pattern is
wearing on the patient, family members, and the healthcare team. This review acknowledges that
a diagnosis of HF is a complex transition characterized by illness.
Properties of the transition. The second concept reviewed by Meleis (2010) includes
the properties of the transition experience. These properties include awareness of the transition,
engagement, changes and differences, time span, and critical points and events that take place
during the transitions. Meleis (2010) notes that awareness of change does not mean a person is
ready for the transition and lack of awareness does not mean that the transition has not begun.
This directly relates to a diagnosis of HF, because the heart’s ability to pump has already
weakened before the patient is aware. Diagnosis is one of the most critical points during the
disease process because the treatment plan is developed and prognosis is discussed. The time
span of managing HF may last a few days, or may last years. It is critical to keep the patient and
family members engaged and eager to participate in the care plan.
Transition conditions & process/outcomes indicators. Transition conditions is the next
concept in Transitions Theory. There are many conditions that influence the way a person moves
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through a transition. Conditions can facilitate or inhibit the transition process and outcomes.
These conditions may be personal or community and societal (Meleis, 2000). The family unit is a
major condition that impacts how a person moves through a transition. The support, or lack of
support, from a family member or caregiver can positively or negatively impact how a person
moves through the diagnosis and management of HF. These conditions influence the next phase
of the concepts, which include patterns of response-process and outcomes indicators. Process
indicators lead the patient toward health or vulnerability and risk. Outcome indicators are used to
determine if the transition is healthy or not (Meleis, 2000). This review seeks to identify positive
conditions surrounding patients with HFrEF by evaluating impedance monitoring on 30 day
hospital readmissions and quality of life.
Nursing therapeutics. Lastly, nursing therapeutics is the final concept described by
Meleis (2010) in Transitions Theory. Nurses are able to assess a patient’s readiness to accept the
transition (Weis, et al., 2007). Nurses are part of a multidisciplinary effort and comprehensive
treatment plan that seeks to help the patient and understand the needs of the patient. Nurses help
prepare the patient through each stage of the transition and educate during critical points and
events to promote the best outcome. Nurses also help people to understand the new role they
may play as a result of their illness. These concepts are interrelated and adaptable, just as
transitions flow and move over time. Transitions cause a change in identity, roles, relationships,
and patterns of behavior. For example, children may have to become the caregiver for their
elderly parent with HFrEF (Smith & Liehr, 2014).
Christian worldview. Ecclesiastes is a book in the Bible written by King Solomon and
inspired by God. He describes the transitions that occur in life. He wrote that there is a time to be
born, and a time to die; a time to heal, and a time to break down. Looking at life from a Biblical
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perspective gives meaning to life’s transitions. Solomon states there is a season and a time for
everything under heaven. Jeremiah 29:11, is another Scripture passage that describes how God
has a plan for each of us, and His plan is good. Applying the theory of transitions to this review
as a theoretical framework incorporates the nursing perspective and its impact on patient care.
Evaluation Methods
This integrative review was evaluated by the author and chair on a continual basis to
ensure that the evolving document upheld exactitude and met the requirements of the Doctor of
Nursing Practice program at Liberty University.
Search Strategy
The search strategy to identify the best evidence related to impedance monitoring to
reduce readmissions for patients with heart failure with reduced ejection fraction (HFrEF)
included a search of the Cochrane Library, CINAHL, and PUBMED. Keywords and phrases
used for the search included impedance monitoring, heart failure, readmission rates, costs, and
quality of life. Supporting questions were also used to help narrow the articles. No limits were
placed on type of article or publication date. The search was limited to the English language and
available free full text. These searches produced 196 hits. CINAHL produced 19 hits, Cochrane
produced 74 hits, and PUBMED produced 103 hits.
Study Identification
The researcher narrowed the search by publication date (2012-2017), study design,
(clinical practice guideline, systematic review, controlled trial, cohort study, literature review,
and theory) and available full text, which yielded 25 studies for review. Abstracts of the 25
articles were reviewed for selection criteria. If any of the selection criteria were not indicated as
a primary component, then the study was excluded from this systematic review. If the abstract
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did not provide adequate information to determine selection criteria, the full text publication was
reviewed. Studies that were appraised and included in identified systematic reviews were not
individually appraised or discussed in this systematic review. A search of the National
Guidelines Clearinghouse was conducted for professional guidelines pertaining to heart failure
disease management to inform this review. After excluding articles that did not meet the
selection criteria there were 14 articles included in this review and critical appraisal.
Selection Criteria
Population. The focus of this review was patients with HFrEF with impedancemonitoring capability in their pacemaker device.
Intervention. The intervention of interest was impedance monitoring in patients with
HFrEF.
Outcome. The principle outcomes of interest were hospital readmission rates, quality of
life, and theory application.
Study Design. Articles were included if they were classified as a clinical practice
guideline, systematic review, controlled trial, cohort study, literature review, or theory
discussion.
Methods for Quality Assessment
A single reviewer critically appraised the quality of each manuscript. Clinical practice
guidelines were appraised according to the Appraisal of Guidelines Research & Evaluation
(AGREE, 2006). Each manuscript was assigned a level of evidence (LOE) according to
Melnyk’s system of hierarchy (Appendix A).
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Exclusion

Publications from 2012-2018

Publications prior to 2012

Subjects greater than 18 years of age

Subjects less than 18 years of age

Study design

Non research articles

English language

Language other than English

Full-text articles

Abstract only articles

Table 1. Inclusion and Exclusion Criteria
Critical Appraisal
Clinical Practice Guidelines
The 2017 focused update guideline for the management of HF does not address
impedance monitoring as a tool for the identification and management of HF (Yancy et al.,
2017). While this is not a current recommendation in the guidelines for HF and there is no
mention of impedance monitoring in the report, the Heart Rhythm Society (HRS) and European
Heart Rhythm Association (EHRA) have developed an expert consensus document in
collaboration with the American Heart Failure Society and other professional organizations
related to the techniques, indications, personnel, frequency, and ethical considerations of
monitoring cardiovascular implantable electronic devices. This consensus mentions impedance
monitoring in addition to rhythm monitoring, pacing, defibrillation, and battery monitoring
(Wilkoff, 2008). It is recommended that a minimum frequency for in person or remote
monitoring occur every 3-12 months, or more frequently if the device is a defibrillator. These
recommendations are more extensive and discuss monitoring (battery, rhythm, leads, and
thoracic impedance) from implantation through battery depletion. This document also discusses
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the wide range of variety in the frequency of remote monitoring devices at a worldwide level and
provided some basic recommendations for device monitoring. Disease-related monitoring, and
specifically thoracic impedance monitoring as part of disease management in HF, is discussed as
a goal for implantable devices (Wilkoff, 2008).
Systematic Reviews
One systematic review was discovered that related to the study topic. Blair (2014)
synthesized 24 randomized controlled trials that were performed to determine if device
diagnostics could be used to identify HF exacerbations in the clinical setting. The purpose of this
review was to determine if this early identification of HF can reduce hospitalizations with
reduction of readmissions being its principle objective. The 24 studies were obtained using the
databases of CINHAHL, MEDLINE, PubMed, and ClinicalTrials.gov. These studies were
divided into two categories based on the primary objectives examined (Blair, 2014).
First, the efficacy and prognostic value of device diagnostic data was evaluated and
second the clinical feasibility of device diagnostic data and its impact on patient outcomes was
evaluated. This systematic review found that device data is capable of predicting HF
exacerbations and also preventing hospitalizations. A strong correlation between cardiac
biomarkers and hemodynamic measures was also discovered. The findings from this review
indicate the ability for device diagnostics to assist clinicians to predict acute decompensated HF
(ADHF) much earlier than other indicators, such as patient reported symptoms (Blair, 2014). The
objective measures available with device diagnostics enables clinicians to be better informed and
initiate communication with the patient rather than waiting for symptoms to be triggered. This
allows for better clinical decision making because better and more accurate information is
available to the clinician (Blair, 2014). This systematic review supports the importance of
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utilizing device diagnostics to identify HF exacerbations and prevent hospitalizations. A study
limitation that was shared by the author is that a bias exists towards Medtronic because the
literature available on this topic was primarily from studies using Medtronic devices (Blair,
2014).
Clinical Trials
Multiple clinical trials have been performed to evaluate the impact of impedance
monitoring on patients with HF and have shown a reduced rate of hospitalizations as well as
increased survival. The lung impedance monitoring in treatment of chronic heart failure (LIMITCHF) trial was an evidence-based European study published in 2016 and evaluated the impact of
alerts on preventing HF hospitalizations for those patients who had device data and alert
capability (Domenichini, et al., 2016). The purpose of this trial was to evaluate the impact of
alerts on preventing HF hospitalizations with the primary objective being to reduce readmissions.
This was a randomized controlled trial and patients with chronic HF with OptiVol or CorVue
capable implantable cardioverter-defibrillators were randomized to either the active group (IIM
alarm turned on and diuretic dose increased by 50% for 1 week in the event of an alarm
sounding) or the control group (alarm turned off). The primary endpoint of the trial was HF
hospitalizations. Eighty patients were included in the study and divided into two groups: active
group (41 patients) and control group (39 patients) however, 71 patients reached the one-year
follow-up. There was a total of 11 HF hospitalizations in the active group vs. 6 in the control
group without a significant difference in the number of episodes for each patient (Domenichini,
et al., 2016). A decreased trend in MLWHF scores was found in the active group compared to an
increased trend in the control group. This indicates an improved quality of life in the active
group versus a reduced quality of life in the control group. While the study results did not show a
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reduction in emergency HF treatment, there was a positive impact on quality of life. A limitation
shared is that there were a relatively high amount of IIM alerts that were not detected and
consequently were not treated per the protocol. This may have reduced the potential benefit of
alert guided treatment (Domenichini, et. al., 2016).
The MOMOTARO (Monitoring and Management of OptiVol Alert to Reduce Heart
Failure Hospitalizations) is a trial that was performed in Japan. This study’s purpose was to
review a new algorithm that can be used to calculate impedance. The study’s objective was to
reduce HF hospitalizations. The study consisted of 195 patients who had been implanted with a
high-energy device and assessed the potential that fluid index could predict fluid accumulation
and ADHF (Miyoshi, et al., 2017). The algorithm modification was then used to reduce the
number of false-positive threshold crossings for HF and to more accurately diagnose actual fluid
accumulation in patients at baseline and at an alert. During the study there were 154 primary HF
events that were detected with the previous algorithm and there was no significant difference of
the BNP between the baseline and alert. Using the modified algorithm, only 37 reached the
threshold and the log BNP was significantly higher in these 37 events compared with the
baseline value (Miyoshi, et al., 2017). This study supports the need to assess the fluid index in
patients with devices and use it to assist in predicting fluid accumulation. Study strengths were
that this was a randomized controlled trial with findings that support the study topic. Limitations
include that this was a simulation rather than a prospective clinical study and raw data for
patients with HF hospitalizations without threshold crossing events was not retained as a control
and both would be recommended. Many factors can impact fluid retention in the chest wall
including infection, pneumonia, and anemia and this new algorithm cannot detect between these
other pathological conditions (Miyoshi, et al., 2017).
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The IMPEDANCE-HF trial was a randomized controlled trial that consisted of 256
patients from 2 medical centers with chronic HF and ejection fraction (EF) <35% with New
York Heart Association Class II-IV symptoms who were admitted for ADHF within 12 months.
The purpose of this trial was to measure the degree of pulmonary congestion with non-invasive
impedance and its objective was to reduce HF hospitalizations (Shochat, et al., 2016). The noninvasive impedance monitoring means that it was not an implanted device, which is the
traditional method for impedance monitoring. This new technology uses an electromagnetic field
to externally measure thoracic impedance. The 256 patients were randomized into the control
group and the therapy group. The therapy group had noninvasive lung impedance measures
performed monthly (every 30-days) and were followed for at least 12 months. Patients were
blind to their assignment group. The primary endpoint was AHF hospitalizations and the
secondary endpoint was all-cause hospitalizations and mortality. There were 67 (monitored
group) v. 158 (control group) AHF hospitalizations during the first year, and 211 v. 386 AHF
hospitalizations during the entire follow-up among the monitored patients (Shochat et al., 2016).
During the follow-up there were 42 and 59 deaths, 13 and 31 resulting from HF. IMPEDANCEHF trial results showed that lung impedance guided treatment reduces hospitalizations for heart
failure and decreases HF-related mortality. These results validate the concept that lung
impedance preemptive treatment reduces hospitalizations and incidence of HF, as well as CV
and all-cause mortality (Shochat et al., 2016). This study added tremendous evidence that early
detection of hemodynamic changes enables clinicians to intervene early and in the outpatient
environment (HFSA, 2016). The trial was extended to include a one-year follow-up sought to
demonstrate the impact of impedance monitoring on survival (Shochat et al., 2016). This followup was the first lung impedance trial that demonstrated this type of guided pre-emptive therapy
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of worsening pulmonary congestion prevents HF hospitalizations, both HF and all-cause. This
study also demonstrated that all-cause, cardiovascular and HF mortality was reduced. The study
measured lung impedance with a new non-invasive high-sensitive device and supports the use of
monthly impedance monitoring in patients with HF (Shochat et al., 2016). Strengths of the
IMPEDANCE-HF study include that it offers cardiovascular clinicians insight into several
clinical questions around the management of HF. First, it addresses that impedance monitoring
can identify the degree of pulmonary congestion. Second, it addresses that pre-emptive
monitoring, specifically every 30-days (more frequent than the current expert consensus
recommendation) does reduce HF hospitalizations. Lastly, it addresses that impedance
monitoring reduces all-cause and HF mortality. Limitations to this study include that the
impedance monitoring device used was a new technological non-invasive tool, not specifically
named in the study, and this technology is not as prevalent as traditional pacemaker impedance
technologies. Also, this was a limited trial at one hospital site. A larger study across multiple
centers would further clarify the benefits of impedance monitoring.
Cohort Studies
The researcher found multiple cohort studies in the literature that evaluated the use of
impedance monitoring in the management of patients with HF. A prospective observational
cohort study examined the correlation between pulmonary artery pressure and thoracic
impedance and daily monitoring. The purpose of this study was to observe the impact of
CardioMems, a small device implanted into the pulmonary artery, and measure pulmonary artery
pressures (PAP) on thoracic impedance (Perego, et al., 2017). This was a study of 10 patients
with HFrEF who had previously been implanted with an ICS capable of measuring thoracic
impedance. Those patients were then implanted with CardioMems and both impedance and PAP
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were remotely monitored daily. Investigators were blind to the PAPs for the first three months,
then the PAP level was used to guide therapy. The study found that there is a direct correlation
between left ventricle filling pressures and lung water content, however, there is a limited value
in predicting episodes of thoracic impedance decrease (Perego et al., 2017). However, thoracic
impedance decrease and PAP elevation precede ADHF. This study supports the need to perform
impedance monitoring in patients who have the device capability. Study limitations include the
small sample size and that the study participants were coincidentally all males, so gender related
differences could not be excluded. Variations of thoracic impedance and PAPs were defined if
they lasted greater than 7 days, so this definition may have influenced the study results (Perego
et al., 2017).
The next study is a single-center prospective cohort study seeking to evaluate device
monitoring in HF patients with a cardiac resynchronization therapy (CRT) device. Eighty
patients were prospectively enrolled when they were implanted with biventricular defibrillators
that had impedance monitoring capability (Forleo et al., 2013). Clinical heart failure status and
impedance data were assessed during follow-up and if patients presented with an alert or heart
failure deterioration. During follow-up there were 56 events of fluid index alerts identified in 29
patients. Confirmed ADHF occurred in 23 out of the 29 patients. Confirmed ADHF resulted in
14 hospitalizations and 7 of the 14 were preceded by an alert. False positives occurred in 23 of
the 80 patients. False negatives are the primary study limitation with small sample size being
another limitation. In summary, of the 56 fluid alerts, half were confirmed cases of heart failure.
This study supports that impedance monitoring programs are feasible and can help to predict a
HF exacerbation (Forleo et al., 2013).
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A subsequent cohort study sought to determine the effectiveness of impedance
monitoring in heart failure patients with implanted cardiac defibrillators. The purpose of this
study was to determine the effectiveness of impedance monitoring on heart failure and to assess
patient’s perceptions of self-care. The researcher recruited 25 participants at a large private
cardiology practice during an ICD interrogation if an impedance alert was triggered. After 30
days a chart review was performed to assess if any intervention occurred in direct relation to the
patient’s heart failure. The researcher administered the Self-Care of Heart Failure Index test as a
pre and posttest to all patients to assess management, maintenance, and confidence in relation to
their self-care habits (Franchuk, 2017). Twenty-one study participants were male and 4 were
female with the mean age of 69.5 years. The primary study result showed that patients
confidence increased related to management of symptoms due to the surveillance of impedance
monitoring. This article approached impedance monitoring from a different perspective and gave
insight into how this type of device monitoring can influence patients’ abilities to perform selfcare. Study limitations shared by the author include that data collection only occurred at one
office. Time constraint was also a study limitation because this study was performed during an
academic year. Attrition rates were high for the phone recruitment resulting in a smaller sample
size (Franchuk, 2017).
Shapiro, Bires, Waterstram-Rich, and Cline (2017) performed a retrospective chart
review study to evaluate clinical outcomes for patients with class III heart failure. The study
objective was that patients with Class III chronic HF who received interventions in the form of
an implanted CorVue ICD and home health care would have fewer 30 day readmissions than
patients who only received home care. The principle outcome of interest was to see if patients
with CorVue ICD have lower 30-day readmission rates than patients without the device (Shapiro,
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et al., 2017). One hundred and twenty patients were divided into a study group and a control
group with 60 patients in each group. The researcher analyzed thirty-day readmission and
mortality rates in each group. No patients with CorVue experienced a 30 day readmission. In
contrast, 14 of 60 patients in the control group did experience a 30 day readmission (Shapiro, et
al., 2017). This particular study had a 90 day time period with a small sample size therefore
validity cannot be certain or results generalized. More studies are needed to determine which
interventions have the greatest financial impact as well as patient outcomes improvement
(Shapiro, et al., 2017).
The Detect Fluid Early from Intrathoracic Impedance Monitoring (DEFEAT-PE) is a
prospective multicenter study that used impedance monitoring to detect pulmonary congestion
(Heist et al., 2014). This study analyzed different intrathoracic vectors and their ability to predict
ADHF. One hundred sixty-two patients were enrolled, 80 participants had ICDs and 82 had
CRT-Ds. All participants had greater than or equal to one event of pulmonary congestion. An
alternative algorithm was used to detect pulmonary congestion and resulted in a sensitivity of
21.6% and a false-positive rate of 0.9% per patient year. The DEFEAT-PE algorithms resulted in
low sensitivity for the prediction of heart failure events; however, they were able to achieve an
acceptably low false-positive rate. The Federal Drug Administration ultimately approved this
algorithm.
Results & Summary of Evidence
In Patients with HFrEF Who Have an Impedance-monitoring Device, Does Impedance
Monitoring Reduce Hospital 30 day Readmission Rates?
While impedance monitoring is not a recommendation for care in the guidelines for
patients with HF (Yancy et al. 2017), there is sufficient evidence in the literature that support its
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use. The evidence supports that impedance monitoring identifies ADHF. Impedance monitoring
can be a useful tool to predict fluid accumulation in patients with HF prior to symptom onset and
can allow clinicians to intervene quickly with outpatient therapies (Franchuk, 2017). The studies
provide evidence that its use can reduce hospital readmissions and mortality (Blair, 2014;
Miyoshi et al., 2017; Shochat, et al. 2016). The literature supports that implementation of
impedance monitoring programs in patients with HF can impact hospital readmissions and
mortality rates. These outcomes are beneficial for patients and hospital networks as patient
outcomes are often directly linked with financial incentives from insurance companies. A single
systematic review, three clinical trials (IMPEDANCE-HF), and five cohort studies support the
use of impedance monitoring to identify early ADHF (Blair, 2014; Domenichini et al., 2016;
Miyoshi et al., 2017; Shochat et al., 2016; Shochat et al., 2016; Forleo et al., 2013; Heist et al.,
2014; Perego, et al., 2017; Franchuk, 2017; Shapiro, et al., 2017).
Gaps identified include limited discussion on increased (more frequent than 3-12 month
monitoring) and 30 day readmission rates. This researcher found one study that explored this
supporting clinical question (Shochat et al., 2016) using a new technology. This study did find
that 30 day monitoring reduces hospital readmissions (Shochat, et al., 2016). More studies are
needed to support their study findings.
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In patients with HFrEF who
have an impedance-monitoring
device, does increased
impedance monitoring reduce
hospital 30-day readmission
rates?

Does thoracic impedance
monitoring identify early heart
failure?

Does increased impedance
monitoring decrease
readmissions?

Blair, 2014; Domenichini et. al.,
2016; Miyoshi et. al., 2017;
Shochat et. al., 2016; Shochat et.
al., 2016; Forleo et. al., 2013;
Heist et. al., 2014; Perego, et. al.,
2017; Franchuk, 2017; Shapiro, et.
al., 2017

Blair, 2014; Miyoshi et. al.,
2017; Schochat, et. al. 2017

Figure 1. Impact of Impedance Monitoring on Readmissions.
In Patients with HFrEF Who Have an Impedance-monitoring Device, Does Impedance
Monitoring Impact Quality of Life?
Impedance monitoring has the ability to impact the quality of life for patients with heart
failure. The LIMIT-CHF Trial specifically analyzed quality of life in patients with HF who
underwent impedance monitoring and reported that there was an improvement in quality of life
(Domenichini e. al., 2016). The other clinical trials and cohort studies did not discuss quality of
life as an outcome of interest.
The HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable
devices discussed that a goal of implanted cardiovascular devices with monitoring capability is
to optimize quality of life; this encompasses thoracic impedance monitoring. However, no
further discussion was provided on whether or not quality of life is an influencing factor on
thoracic impedance recommendations (Wilkoff, 2008). Patients, however, expressed that this
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type of monitoring helped them to identify positive behaviors and lifestyle modifications that can
reduce cardiovascular risk (Franchuck, 2017; He & MacGregor, 2011).

In patients with
HFrEF who have
an impedancemonitoring
device, does
impedance
monitoring
impact quality of
life?

Are there any studies
that evaluate the effect
of impedance monitoring
on quality of life?

Domenichini, et. al.,
2016

Is there a nursing theory
applicable to impedance
monitoring and heart
failure care?

Jones, Nowels, Sudore,
Ahluwalia, &Bekelman,
2015 Davidson, Dracup,
Phillips, Padilla, & Daly,
2007

Does impedance
monitoring improve
quality of life?

Domenichini et. al., 2016

Figure 2. Impact of Impedance Monitoring on Quality of Life.
Additional Analysis
A common theme throughout each article regardless of their study design was that there
is a transition occurring in the patient’s health. This transition is marked by a heart failure
diagnosis and/or hospitalized exacerbation and continues with discharge to home and
management of the chronic illness. This theme led the reviewer to explore nursing theories
around transitions and Transitions Theory was found to be very applicable to patients with heart
failure.
Limitations
Limitations shared in the literature included that there may be a bias towards Medtronic
in the results of clinical trials because many clinical trials used Medtronic devices.
Discussion
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Implications for Research
Continued research is recommended to further solidify the use of impedance monitoring
in the management of heart failure. This review highlights the current evidence related to
impedance monitoring and early identification of HF, interventions used to manage HF, and
impact on quality of life. More information is needed to see if more frequent impedance
monitoring reduces 30 day hospital readmissions.
Implications for Practice
The significance of this review can greatly impact patients with HF and how they
perceive their quality of life. The potential to predict a HF exacerbation enables the HF team to
intervene prior to decompensation. Patients with HF often suffer from depression and struggle
with the reality of living with a chronic disease (Herr et al., 2017). Quality of life is a major
outcome in patients with HF and the ability to improve quality of life through impedance
monitoring is impactful. At the micro level, or patient and clinician level, this can help to
improve the patient and provider relationship. In addition to an improved relationship, the patient
will have a better quality of life evidenced by a decrease in exacerbations requiring
hospitalizations. At the organizational level, or the mesa level, the number of patients that are
prevented from hospital admission can greatly impact the financial implications. Readmissions
are costly for the patient and the organization because readmissions are associated with payment
penalties. With a reduction in readmissions the penalties will decrease and enable the
organization to save financially. Nationally this may help patients across the country that
struggle with HF and as technology advances there may further innovations created enabling
patients to review their threshold levels in real time and help them to make better decisions
related to self-care (Forleo et al., 2013).
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The profession of nursing can utilize impedance monitoring as a patient education tool
and as an assessment tool. Home health nurses and other nurses can utilize the data to help the
patient identify when fluid is developing so that changes can be made in their lifestyle or
medications (Shapiro, 2017). Nurses across the country are caring for patients with HF; nearly
every nurse has encountered a patient with this diagnosis. This review and other scholarly
projects help to elevate the profession of nursing amongst the healthcare community. Subsequent
scholarly work related to impedance monitoring can continue as new technologies and devices
are being developed.
DNP Essentials
Essential I: scientific underpinnings for practice
The DNP Essentials highlight the preparation of the doctorate prepared nurse and the
many avenues of healthcare that the nursing profession embodies. The first essential is the
Scientific Underpinnings for Practice, which reflects the complexity of practice at the doctoral
level and the rich heritage that is the conceptual foundation of nursing. This integrative review
reflects this essential by integrating nursing science with knowledge that is biophysical,
psychosocial, analytical, and organizational. This review used science-based theories and
concepts to determine the nature and significance of health and health care delivery, described
the actions and advanced strategies to enhance the care of heart failure patients, and evaluated
the outcomes of the literature (AACN, 2017).
Essential III: clinical scholarship and analytical methods for evidence-based
practice
This review reflects the hallmark of the doctoral education by providing a detailed
analytical scholarship review related to the care of patients with HF. This review incorporates
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this DNP Essential by investigating and synthesizing evidence across disciplines and types of
research to help solve health care problems and improve health outcomes. This review used
analytical methods to critically appraise the literature to inform providers and institutions
regarding the use of impedance monitoring technologies in the care of patients with HF (AACN,
2017). An integrative review appraises and combines available evidence, including theory and
other information. This review method incorporates diverse methodologies to capture
circumstances, processes, and individual elements of the topic under study (Whittemore & Knafl,
2005). This type of review takes traditional review methods further and provides a broader focus
(Holly, Salmond, & Saimbert, 2017) evidencing the exactitude of the DNP.
Essential IV: information systems/technology and patient care technology for the
improvement and transformation of health care
This essential distinguishes the DNP graduate’s ability to use information systems and
technology to support and improve patient care and healthcare systems and provide leadership
within healthcare systems. This review assists providers in the use of information
systems/technology to evaluate programs of care, outcomes of care and care systems. By
performing this integrative review, healthcare providers will be better informed about the impact
of thoracic impedance technologies on 30 day hospital readmissions and quality of life for
patients with heart failure (ACCN, 2017).
Conclusion
In closing, managing patients with HF is a multidisciplinary effort with the patient being
the most important member of the healthcare team. Diagnosis of HF is often a concerning
diagnosis for patients and family members. HF it is very difficult to medically and self-manage
and is characterized by exacerbations, and hospitalizations. Many patients with HF are on an
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end-of-life trajectory, as HF is one of the nation’s leading causes of death. One way to help to
manage symptoms and decrease hospitalizations is to utilize impedance-monitoring capabilities
through device technology. This review adds to the body of evidence for cardiovascular
clinicians, thus improving the health of those who suffer with HF. Not only can impedance
monitoring be a tool to reduce readmissions, but it can also be a tool evaluate quality of life, the
patient’s ability to perform self-care, and identify when end of life discussions may need to take
place. Impedance monitoring can be a diverse tool for the management of this chronic and
progressive disease. The updated methodology by Whittemore and Knalf (2005) and Transitions
Theory strengthen this integrative review. This review also is in conjunction with the DNP
Essentials and seeks to evidence the scholarship and evidence-based values of the DNP. By
incorporating the findings from this review the hope is that cardiovascular clinicians are better
empowered to manage HF and help patients with quality of life.
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Appendix A
Table 2. Evidence for Impedance Monitoring
Name: Evaluating Impedance Monitoring on Readmissions for Patients with Heart Failure with
Reduced Ejection Fraction (HFrEF)
Clinical Question: In patients with HFrEF, who have an impedance monitoring device, does
impedance monitoring reduce 30 day hospital readmission rates?
Clinical Question: In patients with HFrEF who have an impedance-monitoring device, does
impedance monitoring impact quality of life?

Title/
Author/
(year)
1. 2007
ACC/AHA/H
FSA focused
update of the
2013
ACCF/AHA
guideline for
the
management
of heart
failure.
Yancy, 2017

2. Device
diagnostics
and early
identification
of acute
decompensat

Study
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Objective
(s)
This
document is
an updated
version of
the 2013 HF
guidelines

Design,
Sampling
Method, &
Subjects
Clinical
Practice
Guidelines

LOE

Intervention
& Outcomes

Level
I

This
document
services as
the most
updated
version of
the clinical
practice
guidelines
for HF
management.

The purpose
of this
article was
to
synthesize
the

Systematic
Review of 24
studies
pertaining to
device
diagnostics

Level
I

This article
synthesized
the
randomized
controlled
trials

Results

Study
Strengths
&
Limitations
The
Strength:
guidelines this is the
do not
highestdiscuss
level
impedance document
monitoring and is
in any
considered
form at
the standard
this time
for
for
clinicians in
manageme managing
nt of HF
heart failure
Limitation:
Does not
discuss
impedance
monitoring
as an
alternative
modality to
identificatio
n of HF
Device
Strengths:
diagnostics This study
showed a
supports the
strong
importance
correlation of device
with
diagnostics
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ed heart
failure: a
systematic
review
Blair, T.
(2014)

literature
and its
principle
objective
was to
determine if
device
diagnostics
can identify
HF
exacerbatio
ns

and impact
on patient
data. The
articles that
were
reviewed
were
obtained
using
Cumulative
Index to
Nursing and
Allied Health
Literature,
MEDLINE,
PubMed and
ClinicalTrials
.gov

3. Early
identification
of
asymptomatic
subjects at
increased risk
of heart
failure and
cardiovascula
r events:
progress and
future
directions.
Coller, J.M.,
Campbell,
D.J., Krum,
H., Prior,

The purpose
of this
article is to
review the
current
tools that
are used to
identify HF
including
biomarkers
and EKG’s
and device
diagnostics.
Its objective
was to
encourage
an agreed

This study
was a
systematic
review of
multiple
studies.

54
regarding the
efficacy of
device
diagnostics
and how they
can identify
heart failure
exacerbation
s in the
clinical
setting

Level
I

established
HF
biomarkers
and
hemodyna
mic
measures.
This
indicates
that device
diagnostic
parameters
predict
impending
HF much
earlier
than
traditional
methods of
monitoring
.

to identify
HF
exacerbatio
ns and
prevent
hospitalizati
ons.
Limitations:
More
studies are
needed to
review the
device
diagnostics.
Bias was
noted
towards
Medtronic
devices
because the
literature
available on
this topic
was
primarily
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using
Medtronic
devices.
This article
This
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discussed the article is
The
need for a
helpful
literature
screening
because it and most up
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identified
to date
patients with the
studies were
heart failure
continued reviewed
and
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and
specifically
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reported in
talked about and
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biomarkers
monitoring systematic
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of patients review.
SCREEN-HF with HF.
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Article
This study
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Australia. It
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(2013)

policy and
screening
tool to
identify
patients
with HF.

4. The lung
impedance
monitoring in
treatment of
chronic heart
failure (the
LIMIT-CHF
study).
Domenichini
, G.,
Rahneva, T.,
Diab, I. G.,
Dhillon, O.
S.,
Campbell,
N. G.,
Finlay, M.,
& ...
Finlay, M.
C.
(2016)

The purpose
of this trial
was to
evaluate the
impact of
alerts on
preventing
HF
hospitalizati
ons. The
objective
was to
reduce
readmission
s.

Randomized Level
controlled
II
trial. Chronic
HF patients
with OptiVol
or CorVue
capable
implantable
cardioverterdefibrillators
were
randomized
to either the
active group
(IIM alarm
turned on and
diuretic dose
increased by
50% for 1
week in the
event of
alarm
sounding) or
the control
group (alarm
turned off).
Primary
endpoint was
HF
hospitalizatio
ns per patient
at 1 year.

55
reviewed the
current
published
evidence for
screening
and
addressed
barriers and
recommendat
ions for
future
research
This study
(LIMITCHF)
evaluated the
use of alerts
in guiding
HF treatment
and to
prevent HF
hospitalizatio
ns. This
study did not
reduce
emergency
HF treatment
but did have
an impact on
quality of
life.

interventio
n in
asymptom
atic
cardiac
pathology
can
improve
clinical
outcomes
in many
situations.
Results: 80
patients
included in
the study,
71 reached
1 year
follow-up.
There was
a total of
11 HF
hospitaliza
tions in the
active
group vs. 6
in the
control
group
without a
significant
difference
in the
number of
episodes
per patient.
A
decreased
trend in
MLWHF
scores was
found in
the active
group
compared
to an

screening
tool, but
was able to
encourage
the need for
continued
research to
identify a
screening
tool.

Strengths:
This was a
randomized
controlled
trial that did
show an
impact on
impedance
monitoring
on quality
of life
Limitation:
The main
limitation is
related to
the
relatively
high
number of
IIM alerts
not detected
and
consequentl
y not treated
as per
protocol.
This may
have
reduced the
potential
benefit of
alert guided
treatment.
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5. Correlation
between
pulmonary
artery
pressure and
thoracic
impedance:
Insights from
daily
monitoring
through an
implanted
device in
chronic heart
failure.
Perego GB,
Oldani M,
Pellegrini D,
Brasca
FMA,
Malfatto G,
Villani A,
Brambilla R,
Rella V,
Parati G
(2017)

The purpose
of this study
was to
observe the
impact of
cardiomems
and
measureme
nt of
Pulmonary
Artery
Pressures
(PAP) on
thoracic
impedance.

Prospective
Observationa
l
Study/Cohort
Study of 10
patients with
reduced
ejection
fraction,
previously
implanted
with an ICS
capable of
measuring
thoracic
impedance.
These
patients were
implanted
with
CardioMems
and both
impedance
and
Pulmonary
artery
pressures
were
remotely
monitored
daily.
Investigators
were blind to
the
pulmonary
artery
pressures for
the first three
months, then
this level was
used to guide
therapy.

Level
II
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increase in
the control
group.
Results:
This
Strict
article
correlation
supports
between LV the need to
filling
perform
pressures and impedance
lung water
monitoring
content,
in patients
however
with heart
there is a
failure to
limited value prevent
in predicting exacerbati
episodes of
ons.
thoracic
impedance
decrease.

Strengths:
Supports
the concept
that
impedance
monitoring
can predict
fluid
overload in
patients
with heart
failure.
Limitations:
The study
population
of 10
patients
may have
been why
the study
was not able
to see a
significant
ability to
prevent
exacerbatio
ns. Also, all
of the study
participants
were males,
so gender
related
differences
cannot be
excluded.
Also,
variations
of thoracic
impedance
and
pulmonary
artery
pressures
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6. An
improved
algorithm
calculated
from
intrathoracic
impedance
can precisely
diagnose
preclinical
heart failure
events: subanalysis of a
multicenter
MOMOTAR
O
(Monitoring
and
Management
of OptiVol
Alert to
Reduce Heart
Failure
Hospitalizatio
n) trial study
Miyoshi A,
Nishii N,
Kubo M,
Okamoto Y,
Fujii S,
Watanabe A,
Okawa K,
Kawamoto
K, Morita H,
Ito H
(2017)

This study
purpose was
to review a
new
algorithm
that can be
used to
calculate
impedance
and its
objective
was to
reduce HF
hospitalizati
on

Randomized Level
Controlled
II
Trial. Study
consisted of
195 patients
who had been
implanted
with a highenergy
device.
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MOMOTAR
O trial in
Japan
assessed the
potential that
fluid index
could predict
fluid
accumulation
/HF and
algorithm
modification
to reduce the
number of
false positive
thresholdcrossings for
HF and to
accurately
diagnose
fluid
accumulation
in patients
baseline and
alert.

Supports
the need to
assess the
fluid index
to predict
accumulati
on of fluid.
There
were 154
primary
HF events
that were
detected
with the
previous
algorithm
(Optivol
1.0), and
no
significant
difference
of the BNP
between
the
baseline
and alert.
Using the
modified
algorithm,
only 37
reached
the
threshold
and the log
BNP was
significantl

were
defined if
they lasted
greater than
7 days, but
also may
have
influenced
the study
results.
Strengths:
Large
randomized
controlled
trial in
Japan and
could
represent a
new way to
detect
impending
HF with
improved
reliability
compared to
the previous
Optivol
Algorithm.
Limitations:
Several
limitations
of the study
include that
this is a
simulation,
and a
prospective
clinical
study is
required to
conclude
whether the
modified
algorithm
reduces
false-
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these 37
events
compared
with the
baseline
value.

7. Noninvasive lung
IMPEDANC
E-Guided
preemptive
treatment in
chronic heart
failure
patients: A
randomized
controlled
trial
Michael
Kleiner
Shochat M,
Shotan A,
Kazatsker

This trial’s
purpose was
to measure
the degree
of
pulmonary
congestion
with noninvasive
impedance
and its
objective
was to
reduce HF
hospitalizati
ons.

Randomized Level
Controlled
II
Trial. 256
patients from
2 medical
centers with
chronic HF
and EF <35%
in NYHA
class II-IV
who were
admitted for
AHF within
12 months
were
recruited.
Patients were

positives.
Also, raw
data for
patients
with HF
hospitalizati
ons without
thresholdcrossing
events was
not retained
as a control.
Lastly,
many
factors can
impact fluid
retention
including
infection,
pneumonia
and anemia
and this
algorithm
cannot
detect
between
these other
pathological
conditions.
IMPEDANC This
Strengths:
E-HF trial
article
This study
results show supports
supports the
that lung
impedance use of
impedance
monitoring impedance
guided
and
monitoring
treatment
determined and
reduces
that it is
encourages
hospitalizatio the key
continued
ns for heart
determinan research on
failure and
t of HF
nondecreases
hospitaliza invasive
HF-related
tions.
technologie
mortality.
s.
RCT. There
Limitations:
were 67
No
(monitored
limitations
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M, Asif A,
Kleiner I,
Weinstein
JM, Dahan
I, Blondheim
D, Meisel S
(2017)

8. One year
follow up
after
termination
non-invasive
lung
impedanceguided
preemptive

randomized
into the
control and
therapy
group. The
therapy
group had
noninvasive
lung
impedance
measures
performed
and followed
for at least 12
months.
Patients were
blind to their
assignment
group.
Primary
endpoint was
AHF
hospitalizatio
ns and
secondary
endpoint was
all-cause
hospitalizatio
ns and
mortality.

This oneyear follow
up study
was after
the
conclusion
of the trial
and
demonstrate

Randomized Level
Controlled
II
Trial. This
article
reviews the
same
population as
the above and
is the 1 year

59
group) v. 158
(control
group) AHF
hospitalizatio
ns during the
first year,
and 211 v.
386 AHF
hospitalizatio
ns during the
entire followup among the
monitored
patients.
During the
follow-up
there were 42
and 59
deaths. 13
and 31
resulting
from HF.
Results
validate the
concept that
lung
impedance
preemptive
treatment
reduces
hospitalizatio
ns and
incidence of
HF, as well
as CV and
all-cause
mortality.
The
IMPEDANC
E-HF trial is
the first lungimpedance
trial
demonstratin
g that this
type of

were
discussed.

This trial
was a
follow-up
to the
monthly
impedance
monitoring
program
and

Strengths:
This trial is
pivotal in
managemen
t of HF
because it
supports the
need for
preventive
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treatment in
chronic heart
failure
patients: a
randomized
controlled
trial
(impedanceHF trial)
Shochat
MK, Shotan
A, Kazatsker
M, Asif A,
Dahan I,
Kleiner I,
Blondheim
D, Weinstein
JM, Meisel S
(2017)

d the impact follow-up.
of this
monitoring
on survival.

9. Analysis of
different
device-based
intrathoracic
impedance
vectors for
detection of
heart failure
events (from
the Detect
Fluid Early
from
Intrathoracic
Impedance
Monitoring
Study).
Heist, E. K.,
Herre, J. M.,
Binkley, P.
F., Van
Bakel, A. B.,
Porterfield,

The purpose
of this
article was
to evaluate
algorithms
used to
detect
pulmonary
congestion
and to
achieve an
acceptably
low falsepositive
rate.

Prospective
Multi-Center
study of
multiple
intrathoracic
impedance
vectors to
detect
pulmonary
congestion
events

Level
III

60
guided preemptive
therapy of
worsening
pulmonary
congestion
prevents HF
hospitalizatio
ns in HF,
reduces allcause, CV,
and HF
mortality in
these
patients.
Lung
impedance
was
performed
with a new
noninvasive
highsensitive
device.
162 patients
were
enrolled, 80
with ICDs
and 82 with
CRT-Ds all
with greater
than or equal
to 1
pulmonary
congestion
event.

supports
the
importance
of monthly
impedance
monitoring
.

monitoring.
It also
encourages
continued
research in
this area of
medicine.
Limitations:
No
limitations
were
discussed.

An
alternative
algorithm
was used
to detect
pulmonary
congestion
and
resulted in
a
sensitivity
of 21.6%
and a
falsepositive
rate of
0.9% per
patient
year. The
DEFEATPE
algorithms

Strengths:
compared to
other cohort
studies this
study
analyzed
multiple
intrathoraci
c
impedance
vectors
from
multiple
centers
Limitations:
Relatively
small
sample size
and
inability to
have a high
sensitivity
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J. G.,
Porterfield,
L. M.,
& ... Pavri,
B. B. (2014).

10.
Retrospective
application of
program to
access and
review
trending
information
and evaluate
correlation to
symptoms in
patients with
heart failure
criteria
for the
remote
management
of patients
with cardiac
resynchroniza
tion therapy.
Brasca, F.
A.,
Franzetti, J.,
Rella, V.,
Malfatto, G.,

The purpose
of this
article was
to review
retrospectiv
e data and
evaluate the
correlation
between
symptoms
of HF and
the ability
to remotely
manage HF
symptoms.

Retrospective Level
Analysis. The III
PARTNERS
HF trial was
evaluated to
see if the
criteria to
detect initial
decompensati
ng in
moderate HF
patients was
possible
under remote
monitoring.

The
PARTNERS
HF criteria
was
retrospectivel
y applied to
1860
transmissions
from 104
patients who
were enrolled
in the
telemedicine
after cardiac
resynchronis
ation therapy
program. The
criteria were
tested to
predict acute
decompensat
ion occurring
the 15 days
following a
transmission.

resulted in
low
sensitivity
for the
prediction
of heart
failure
events and
able to
achieve an
acceptably
low falsepositive
rate. This
algorithm
was
ultimately
approved
by the
USDA.
In 441
cases,
acute HF
was
diagnosed
after the
index
transmissi
on. This
means that
PARTNE
RS HF
criteria
could
identify
HF
patients
who
subsequent
ly
developed
acute
decompens
ation and
these
results

for the
prediction
of HF
events.

Strengths:
This study
showed
how device
data can be
utilized to
provide
objective
data to
patient
symptoms.
Limitations:
More
research is
needed to
correlate
device data
with
symptoms
and the
ability to
treat HF
exacerbatio
ns through
remote
managemen
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Brambilla,
R., Facchini,
M., & ...
Perego, G. B.
(2017)

11.Thoracic
impedance &
pulmonary
artery
pressure
monitoring in
prevention of
heart failure
hospitalizatio
n.
Volodarskiy,
A., Nazeer,
H., Rosen,
L., Patel, A.,
Jermyn, R.
(2017)
remove*

This study’s
objective
was to
evaluate
whether
thoracic
impedance
and
pulmonary
artery
pressure
correlate
and predict
HF
hospitalizati
ons.

Cohort Study
of 15 patients
that were
implanted
with
CardioMems
at euvolemic
states and a
concurrent
Medtronic
Automatic
Implantable
CardioverterDefibrillator
with OptiVol
sensore were
recruited

Level
III

Data was
abstracted
from the
patient’s
devices and
charts were
reviewed for
hospitalizatio
ns for heart
failure. An
analysis was
performed
for an overall
correlation
between the
two
modalities as
well as any
changes in
modality in
the 14 days
preceding the
hospitalizatio
ns.

12. Device
monitoring of
heart failure
in cardiac
resynchroniza
tion
therapy

The purpose
of this
singlecenter
cohort study
was to
evaluate

Prospective
Cohort
Study. 80
patients were
prospectively
enrolled
during

Level
IV

This was a
prospective
study of 80
HF patients
that
confirmed
the feasibility

warrant
prospectiv
e studies to
be done
applying
these
criteria to
remote
monitoring
.
Results:
The 15
patients
were
average
age of 65.7
years and
predomina
tely male
with an
average
EF of
34%. 7 of
the 15
patients
had 11
hospitaliza
tions for
HF. No
significant
changes in
either the
PA
diastolic
pressure or
impedance
were
discovered
.
Results:
during
follow-up
56 events
of fluid
index
alerts were

t.

Strengths:
These
outcomes in
the small
cohort study
supported
the use of
device
monitoring,
Limitations:
sample size
was a
limitation
and it was
not
randomized.

Strengths:
include the
feasibility
to
implement a
device
monitoring
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device
recipients: a
single-center
experience
with a novel
multivector
impedance
monitoring
system.
Forleo, G.
B.,
Panattoni,
G.,
Schirripa,
V.,
Papavasileio
u, L. P.,
Della Rocca,
D. G.,
Politano, A.,
& ... Romeo,
F.
(2013)

device
monitoring
in CRT HF
patients.

implantation
of
biventricular
defibrillators
with
multivector
impedance
monitoring
capability.

13.
Determining
the
effectiveness
of impedance
monitoring in
heart failure
patients with
implanted
cardiac
defibrillators.
Franchuk,
A.
(2017)

The purpose Cohort Study
of this
of 25 patients
article was
to
determine
the
effectivenes
s of
impedance
monitoring
on heart
failure and
to assess
patient’s
perceptions
of self-care.

Level
IV

63
and clinical
usefulness of
an
impedance
monitoring
system,
however,
recommende
d larger
studies to be
performed.
The 80
patients were
prospectively
enrolled also
and clinical
heart failure
status and
impedance
data were
assessed
during
follow-up
and if
patients
presented
with an alert
or heart
failure
deterioration.
A
comprehensi
ve literature
search was
done using
CINAHL
plus full test,
PubMed, and
Google
Scholar prior
to the study.
This study
was
performed at
a large
private

identified
in 29
patients.
Actual HF
events
occurred
in 23
patients
(worsening
signs and
symptoms)
. False
positives
occurred
in 23 of
the 80
patients.
Decompen
sation
resulted in
13
hospitaliza
tions and 7
of the 13
were
preceded
by an alert.

system but
recommend
ed that
further
studies be
done.
Limitations:
false
positives do
occur.

21 study
participant
s were
male and 4
were
female
with the
mean age
of 69.5.
Study
results
showed
that
patient’s
confidence
increased

Strengths:
This article
evaluated
self-care
and the
impact
device
monitoring
can have on
helping
patients to
improve
self-care
methods.
Limitations:
Data
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14.
Improving
Clinical
Outcomes for
Patients with
Class III
Heart Failure.
Shapiro, M.,
Bires, A. M.,
WaterstramRich, K., &
Cline, T. W.
(2017)

Study
objective
was that
patients
with Class
III chronic
HF who
received
intervention
s in the
form of an
implanted
CorVue
ICD and
home health

Retrospective Level
Chart Review IV

64
cardiology
practice.
Participants
were
recruited
during a
device
interrogation
of their ICD
or over the
phone if the
impedance
alert was
triggered.
After 30 days
a chart
review was
performed to
assess if any
intervention
occurred in
direct
relation to
the patient’s
heart failure.
A pre and
post test was
also
administered
to all patients
(SCHFI test).
A
retrospective
chart review
compared the
30-day
readmission
rates and
mortality
rates. An
analysis and
comparison
of 120
patients. The
patients were
divided into

related to
manageme
nt of
symptoms
due to the
surveillanc
e of
impedance
monitoring
.

collection
only
occurred at
one office.
Time
constraint
was also a
study
limitation
because this
study was
performed
during an
academic
year.
Attrition
rates were
high for the
phone
recruitment
resulting in
a smaller
sample size.

Results:
No
patients
with
CorVue
experience
d a 30-day
readmissio
n. In
contrast,
14 of 60
patients in
the control
group did
experience

Strengths:
This
supports the
need to
implement a
device
monitoring
program.
More
studies are
needed to
determine
with
intervention
s have the
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care would
have fewer
30-day
readmission
s than
patients
who only
received
home care.
Principle
outcome of
interest was
to see if
patients
with
CorVue
ICD have
lower 30day
readmission
rates than
patients
without the
device.

65
a control
group and a
study group
with 60
patients in
each.

a 30-day
readmissio
n.

greatest
financial
impact as
well as
patient
outcomes
improveme
nt.
Limitations:
Additional
studies
recommend
ed, the
study time
period was
90 days
with a small
sample size
therefore
validity
cannot be
certain or
generalized.
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